Hiroyuki Ohnuma

1.4k total citations
48 papers, 1.1k citations indexed

About

Hiroyuki Ohnuma is a scholar working on Hepatology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Hiroyuki Ohnuma has authored 48 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Hepatology, 15 papers in Pulmonary and Respiratory Medicine and 15 papers in Epidemiology. Recurrent topics in Hiroyuki Ohnuma's work include Hepatitis B Virus Studies (12 papers), Gastric Cancer Management and Outcomes (12 papers) and Hepatitis C virus research (9 papers). Hiroyuki Ohnuma is often cited by papers focused on Hepatitis B Virus Studies (12 papers), Gastric Cancer Management and Outcomes (12 papers) and Hepatitis C virus research (9 papers). Hiroyuki Ohnuma collaborates with scholars based in Japan, Croatia and Russia. Hiroyuki Ohnuma's co-authors include Y. Miyakawa, T. Nakamura, A Machida, Fumio Tsuda, Junji Kato, M Mayumi, Emiko Takai, Yasushi Sato, Makoto Mayumi and Oda K and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Hiroyuki Ohnuma

47 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hiroyuki Ohnuma Japan	17	547	347	283	252	174	48	1.1k
Tadayuki Kou Japan	14	223 0.4×	107 0.3×	209 0.7×	450 1.8×	425 2.4×	38	1.3k
H Löhr Germany	29	1.4k 2.6×	1.5k 4.4×	62 0.2×	186 0.7×	131 0.8×	67	2.3k
Anna Suk‐Fong Lok United States	17	1.1k 1.9×	1.1k 3.3×	42 0.1×	119 0.5×	127 0.7×	21	1.4k
Tsunenori Fujita Japan	16	268 0.5×	342 1.0×	97 0.3×	154 0.6×	174 1.0×	44	718
Taisuke Inoue Japan	21	995 1.8×	1.0k 3.0×	70 0.2×	166 0.7×	159 0.9×	57	1.5k
K Ziegler Germany	13	199 0.4×	21 0.1×	290 1.0×	92 0.4×	210 1.2×	20	1.0k
Takayoshi Ito Japan	20	760 1.4×	903 2.6×	40 0.1×	339 1.3×	155 0.9×	57	1.5k
Judie Boisvert United States	10	315 0.6×	395 1.1×	38 0.1×	158 0.6×	500 2.9×	10	1.9k
N Yamaguchi Brazil	8	137 0.3×	243 0.7×	72 0.3×	111 0.4×	105 0.6×	16	815
C. M. McBride United States	16	192 0.4×	34 0.1×	187 0.7×	155 0.6×	641 3.7×	35	1.3k

Countries citing papers authored by Hiroyuki Ohnuma

Since Specialization

Citations

This map shows the geographic impact of Hiroyuki Ohnuma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroyuki Ohnuma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroyuki Ohnuma more than expected).

Fields of papers citing papers by Hiroyuki Ohnuma

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroyuki Ohnuma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroyuki Ohnuma. The network helps show where Hiroyuki Ohnuma may publish in the future.

Co-authorship network of co-authors of Hiroyuki Ohnuma

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroyuki Ohnuma. A scholar is included among the top collaborators of Hiroyuki Ohnuma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroyuki Ohnuma. Hiroyuki Ohnuma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Osuga, Takahiro, Koji Miyanishi, Ryo Ito, et al.. (2025). Hepatocellular Carcinoma Presenting with Pseudoprogression in a Patient Receiving Atezolizumab Plus Bevacizumab Combination Therapy. Internal Medicine. 64(14). 2148–2154.

Ito, Ryo, Koji Miyanishi, Tomohiro Kubo, et al.. (2023). Synergistic antitumor effect of histone deacetylase class IIa inhibitor with lenvatinib in hepatocellular carcinoma. Hepatology International. 17(3). 735–744. 11 indexed citations

Osuga, Takahiro, Koji Miyanishi, Shingo Tanaka, et al.. (2023). Occurrence of Autoimmune Encephalitis in a Patient with Hepatocellular Carcinoma after Atezolizumab and Bevacizumab Combination Therapy: A Case Study. Kanzo. 64(11). 559–566. 1 indexed citations

Ohnuma, Hiroyuki, Yasushi Sato, Naotaka Hayasaka, et al.. (2021). Survival benefit of conversion surgery after intensive chemotherapy for unresectable metastatic gastric cancer: a propensity score-matching analysis. Journal of Cancer Research and Clinical Oncology. 147(8). 2385–2396. 13 indexed citations

Hirakawa, Masahiro, Kohichi Takada, Naotaka Hayasaka, et al.. (2020). Case series of three patients with hereditary diffuse gastric cancer in a single family: Three case reports and review of literature. World Journal of Gastroenterology. 26(42). 6689–6697. 5 indexed citations

Nakamura, Hajime, Shohei Kikuchi, Hiroyuki Ohnuma, Masahiro Hirakawa, & Junji Kato. (2019). Total buried bumper syndrome: A case study in transabdominal removal using a technique of endoscopic submucosal dissection. SHILAP Revista de lepidopterología. 7(10). 2012–2013. 4 indexed citations

Ohnuma, Hiroyuki, Yasushi Sato, Masahiro Hirakawa, et al.. (2018). Docetaxel, cisplatin and S-1 (DCS) combination chemotherapy for gastric cancer patients with peritoneal metastasis: a retrospective study. Cancer Chemotherapy and Pharmacology. 81(3). 539–548. 15 indexed citations

Sato, Yasushi, Tamotsu Sagawa, Hiroyuki Ohnuma, et al.. (2018). A dose-escalation study of docetaxel, oxaliplatin, and S-1 (DOS) as a first-line therapy for patients with unresectable metastatic gastric cancer. Cancer Chemotherapy and Pharmacology. 83(1). 161–167. 4 indexed citations

Uemura, N., Shohei Kikuchi, Yasushi Sato, et al.. (2017). A phase II study of modified docetaxel, cisplatin, and S-1 (mDCS) chemotherapy for unresectable advanced gastric cancer. Cancer Chemotherapy and Pharmacology. 80(4). 707–713. 15 indexed citations

10.

Ohnuma, Hiroyuki, Masahiro Hirakawa, Shohei Kikuchi, et al.. (2017). Cases of primary malignant melanoma and melanocytosis of the esophagus observed by magnifying endoscopy. Medicine. 96(17). e6701–e6701. 6 indexed citations

11.

Sato, Yasushi, Masahiro Hirakawa, Hiroyuki Ohnuma, et al.. (2017). A triplet combination with capecitabine/oxaliplatin/irinotecan (XELOXIRI) plus cetuximab as first-line therapy for patients with metastatic colorectal cancer: a dose escalation study. Cancer Chemotherapy and Pharmacology. 80(6). 1133–1139. 5 indexed citations

12.

Someya, Masanori, Yoshihisa Matsumoto, Kensei Nakata, et al.. (2016). Influence of XRCC4 expression in esophageal cancer cells on the response to radiotherapy. Medical Molecular Morphology. 50(1). 25–33. 12 indexed citations

13.

Sato, Yasushi, Hiroyuki Ohnuma, Takayuki Nobuoka, et al.. (2016). Conversion therapy for inoperable advanced gastric cancer patients by docetaxel, cisplatin, and S-1 (DCS) chemotherapy: a multi-institutional retrospective study. Gastric Cancer. 20(3). 517–526. 76 indexed citations

14.

Sato, Yasushi, Hiroyuki Ohnuma, Masahiro Hirakawa, et al.. (2015). A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology. 75(3). 587–594. 7 indexed citations

15.

Sato, Yasushi, Michihiro Ono, Tamotsu Sagawa, et al.. (2010). ENDOSCOPIC FINDINGS OF ENTEROPATHY‐TYPE T‐CELL LYMPHOMA BY DOUBLE‐BALLOON ENTEROSCOPY AND CAPSULE ENDOSCOPY. Digestive Endoscopy. 22(3). 243–245. 12 indexed citations

16.

Takayama, Tetsuji, Yasushi Sato, Takashi Sagawa, et al.. (2007). Phase I study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer. British Journal of Cancer. 97(7). 851–856. 24 indexed citations

17.

Yoshikawa, Akira, Hiroyuki Ohnuma, Atsushi Iwata, et al.. (2005). Epidemiology of blood donors in Japan, positive for hepatitis B virus and hepatitis C virus by nucleic acid amplification testing. Vox Sanguinis. 88(1). 10–16. 23 indexed citations

18.

Takimoto, Rishu, Junji Kato, Takeshi Terui, et al.. (2005). Augmentation of antitumor effects of p53 Gene therapy by combination with HDAC inhibitor. Cancer Biology & Therapy. 4(4). 427–434. 54 indexed citations

19.

Ohnuma, Hiroyuki, Yasushi Sato, Tetsuji Takayama, et al.. (2003). Esophageal cancer complicated by cytomegalovirus esophagitis during chemoradiotherapy: case report. Gastrointestinal Endoscopy. 57(4). 622–626. 8 indexed citations

20.

Ohnuma, Hiroyuki, Emiko Takai, A Machida, et al.. (1990). Synthetic oligopeptides bearing a common or subtypic determinant of hepatitis B surface antigen.. The Journal of Immunology. 145(7). 2265–2271. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact